Outlook Therapeutics (NASDAQ: OTLK) announced its participation in a Virtual Investor Lunch Break Event scheduled for June 25, 2025, at 12:00 PM ET. The company's leadership team, including Lawrence Kenyon (CFO and Interim CEO), Jeff Evanson (CCO), and Jedd Comiskey (SVP - Head of Europe), will discuss commercial strategy, upcoming milestones, and current activities. The event will feature a moderated discussion followed by a live Q&A session. Investors can access the live video webcast through the Events page on Outlook Therapeutics' website, with a replay available for 90 days after the event.
Outlook Therapeutics (NASDAQ: OTLK) ha annunciato la sua partecipazione a un Evento Virtuale "Investor Lunch Break" previsto per il 25 giugno 2025 alle 12:00 ET. Il team dirigenziale dell'azienda, composto da Lawrence Kenyon (CFO e CEO ad interim), Jeff Evanson (CCO) e Jedd Comiskey (SVP - Responsabile Europa), discuter脿 della strategia commerciale, delle prossime tappe e delle attivit脿 attuali. L'evento includer脿 una discussione moderata seguita da una sessione di domande e risposte dal vivo. Gli investitori potranno seguire la diretta streaming video tramite la pagina Eventi sul sito web di Outlook Therapeutics, con la possibilit脿 di rivedere la registrazione per 90 giorni dopo l'evento.
Outlook Therapeutics (NASDAQ: OTLK) anunci贸 su participaci贸n en un Evento Virtual "Investor Lunch Break" programado para el 25 de junio de 2025 a las 12:00 PM ET. El equipo directivo de la compa帽铆a, incluyendo a Lawrence Kenyon (CFO y CEO interino), Jeff Evanson (CCO) y Jedd Comiskey (SVP - Jefe de Europa), hablar谩 sobre la estrategia comercial, pr贸ximos hitos y actividades actuales. El evento contar谩 con una discusi贸n moderada seguida de una sesi贸n de preguntas y respuestas en vivo. Los inversionistas podr谩n acceder a la transmisi贸n en vivo a trav茅s de la p谩gina de Eventos en el sitio web de Outlook Therapeutics, con una repetici贸n disponible durante 90 d铆as despu茅s del evento.
Outlook Therapeutics (NASDAQ : OTLK) a annonc茅 sa participation 脿 un 茅v茅nement virtuel "Investor Lunch Break" pr茅vu le 25 juin 2025 脿 12h00 ET. L'茅quipe de direction de la soci茅t茅, compos茅e de Lawrence Kenyon (CFO et CEO par int茅rim), Jeff Evanson (CCO) et Jedd Comiskey (SVP - Responsable Europe), discutera de la strat茅gie commerciale, des prochaines 茅tapes et des activit茅s en cours. L'茅v茅nement comprendra une discussion mod茅r茅e suivie d'une session de questions-r茅ponses en direct. Les investisseurs pourront acc茅der 脿 la diffusion vid茅o en direct via la page 脡v茅nements du site web d'Outlook Therapeutics, avec un replay disponible pendant 90 jours apr猫s l'茅v茅nement.
Outlook Therapeutics (NASDAQ: OTLK) gab seine Teilnahme an einer virtuellen "Investor Lunch Break"-Veranstaltung am 25. Juni 2025 um 12:00 Uhr ET bekannt. Das F眉hrungsteam des Unternehmens, bestehend aus Lawrence Kenyon (CFO und Interim-CEO), Jeff Evanson (CCO) und Jedd Comiskey (SVP 鈥� Leiter Europa), wird die kommerzielle Strategie, bevorstehende Meilensteine und aktuelle Aktivit盲ten besprechen. Die Veranstaltung umfasst eine moderierte Diskussion, gefolgt von einer Live-Fragerunde. Investoren k枚nnen die Live-Video眉bertragung 眉ber die Veranstaltungsseite auf der Website von Outlook Therapeutics abrufen, wobei eine Wiederholung f眉r 90 Tage nach der Veranstaltung verf眉gbar ist.
Positive
None.
Negative
None.
Live webcast on Wednesday, June 25th at 12:00 PM ET
ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a on Wednesday, June 25, 2025 at 12:00 PM ET.
As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP 鈥� Head of Europe, will discuss the Company鈥檚 commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A will be available on the page under the section of the Company鈥檚 website (). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA鈩� (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA鈩� (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA鈩� (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA鈩� (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA鈩�, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775
FAQ
When is Outlook Therapeutics (OTLK) Virtual Investor Lunch Break Event?
The event is scheduled for Wednesday, June 25, 2025, at 12:00 PM ET.
Who will be speaking at the OTLK Virtual Investor Event?
Lawrence Kenyon (CFO and Interim CEO), Jeff Evanson (CCO), and Jedd Comiskey (SVP - Head of Europe) will be speaking at the event.
What topics will be discussed at the Outlook Therapeutics investor event?
The discussion will cover the company's commercial strategy, upcoming milestones, and current activities.
How can investors access the OTLK Virtual Investor Event?
Investors can access the live video webcast through the Events page under the Investors section of Outlook Therapeutics' website (outlooktherapeutics.com). A replay will be available for 90 days.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
